Phase 3Active, not recruiting

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (CLEAR)

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)

Sponsor
Eisai Inc. (Industry)
Enrollment
1,069 enrolled
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib; Everolimus; Pembrolizumab; Sunitinib
Ages
adults, older adults
Registry
NCT02811861, EUCTR2016-000916-14

Full record on ClinicalTrials.gov

From the registry

The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).

Primary outcomes

  • Progression-free Survival (PFS) by Independent Imaging Review (IIR)

History

  1. Study completion expected

  2. Last registry update

  3. Results first posted

  4. Primary completion

  5. Started

  6. Registered